Article
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
BMC cancer - 13 May 2020
Zhang Hangyu, Yuan Liyun, Liu Lulu, Yan Cong, Cheng Jinming, Fu Qihan, Tong Zhou, Jiang Weiqin, Zheng Yi, Zhao Peng, Zhang Guoqing, Fang Weijia
Abstract excerpt
BACKGROUND: KRAS mutations have been characterized as the major predictive biomarkers for resistance to cetuximab treatment. However, studies indicate that not all KRAS mutations are associated with equivalent treatment outcomes. KRAS G13D mutations were observed to account for approximately 16% of all KRAS mutations in advanced colorectal cancer patients, and whether these patients can benefit from cetuximab has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.